• Facebook
  • Twitter
  • LinkedIn
  • Google +
  • RSS

Jazz Pharmaceuticals - Articles and news items

Jazz Pharmaceuticals submits FDA application for leukaemia treatment

Industry news / 7 April 2017 / Niamh Marriott, Junior Editor

Jazz Pharmaceuticals completed a rolling submission of a new drug application (NDA) to the US Food and Drug Administration (FDA) for the approval of Vyxeos…

Jazz Pharmaceuticals seeks FDA drug application approval for leukaemia treatment

Industry news / 5 October 2016 / Niamh Louise Marriott, Digital Content Producer

The company expects to complete the submission of the new drug application (NDA) for vyxeos by early 2017, and will request a priority review…

Jazz Pharmaceuticals to acquire Celator for $1.5 billion

Industry news / 31 May 2016 / Victoria White, Digital Content Producer

The transaction advances Jazz Pharmaceuticals’ growth strategy and adds Celator’s investigational therapy Vyxeous to the company’s portfolio…

Jazz Pharmaceuticals acquires 100% of the shares of Alizé Pharma II

Industry news / 11 May 2016 / Victoria White, Digital Content Producer

A subsidiary of Jazz Pharmaceuticals has acquired 100% of the shares of Alizé Pharma II in a deal valued at up to €18 million…